Contineum Therapeutics Class A Common StockNASDAQ: CTNM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$430.23 M
-23%vs. 3y high
63%vs. sector
-vs. 3y high
-vs. sector
-20%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 8 min ago
$16.69-$0.52(-3.02%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

CTNM Latest News

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
businesswire.com04 June 2024 Sentiment: POSITIVE

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024.

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
Seeking Alpha06 April 2024 Sentiment: POSITIVE

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today
InvestorPlace05 April 2024 Sentiment: POSITIVE

Contineum Therapeutics (NASDAQ:CTNM) stock is a hot topic among traders on Friday as they prepare for the clinical-stage biopharmaceutical company's shares to go public today. Let's go over everything traders need to know about Contineum Therapeutics ahead of its initial public offering ( IPO ) later today!

What type of business is Contineum Therapeutics Class A Common Stock?

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

What sector is Contineum Therapeutics Class A Common Stock in?

Contineum Therapeutics Class A Common Stock is in the Healthcare sector

What industry is Contineum Therapeutics Class A Common Stock in?

Contineum Therapeutics Class A Common Stock is in the Biotechnology industry

What country is Contineum Therapeutics Class A Common Stock from?

Contineum Therapeutics Class A Common Stock is headquartered in United States

What is Contineum Therapeutics Class A Common Stock website?

https://www.contineum-tx.com

Is Contineum Therapeutics Class A Common Stock in the S&P 500?

No, Contineum Therapeutics Class A Common Stock is not included in the S&P 500 index

Is Contineum Therapeutics Class A Common Stock in the NASDAQ 100?

No, Contineum Therapeutics Class A Common Stock is not included in the NASDAQ 100 index

Is Contineum Therapeutics Class A Common Stock in the Dow Jones?

No, Contineum Therapeutics Class A Common Stock is not included in the Dow Jones index

When was Contineum Therapeutics Class A Common Stock the previous earnings report?

No data

When does Contineum Therapeutics Class A Common Stock earnings report?

The next expected earnings date for Contineum Therapeutics Class A Common Stock is 29 November 2024